M H Drazner1, J E Rame, L W Stevenson, D L Dries. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75390-9034, USA. mark.drazner@utsouthwestern.edu
Abstract
BACKGROUND: The independent prognostic value of elevated jugular venous pressure or a third heart sound in patients with heart failure is not well established. METHODS: We performed a retrospective analysis of the Studies of Left Ventricular Dysfunction treatment trial, in which 2569 patients with symptomatic heart failure or a history of it were randomly assigned to receive enalapril or placebo. The mean (+/-SD) follow-up was 32+/-15 months. The presence of elevated jugular venous pressure or a third heart sound was ascertained by physical examination on entry into the trial. The risks of hospitalization for heart failure and progression of heart failure as defined by death from pump failure and the composite end point of death or hospitalization for heart failure were compared in patients with these findings on physical examination and patients without these findings. RESULTS: Data on 2479 patients were complete and analyzed. In multivariate analyses that were adjusted for other markers of the severity of heart failure, elevated jugular venous pressure was associated with an increased risk of hospitalization for heart failure (relative risk, 1.32; 95 percent confidence interval, 1.08 to 1.62; P<0.01), death or hospitalization for heart failure (relative risk, 1.30; 95 percent confidence interval, 1.11 to 1.53; P<0.005), and death from pump failure (relative risk, 1.37; 95 percent confidence interval, 1.07 to 1.75; P<0.05). The presence of a third heart sound was associated with similarly increased risks of these outcomes. CONCLUSIONS: In patients with heart failure, elevated jugular venous pressure and a third heart sound are each independently associated with adverse outcomes, including progression of heart failure. Clinical assessment for these findings is currently feasible and clinically meaningful.
RCT Entities:
BACKGROUND: The independent prognostic value of elevated jugular venous pressure or a third heart sound in patients with heart failure is not well established. METHODS: We performed a retrospective analysis of the Studies of Left Ventricular Dysfunction treatment trial, in which 2569 patients with symptomatic heart failure or a history of it were randomly assigned to receive enalapril or placebo. The mean (+/-SD) follow-up was 32+/-15 months. The presence of elevated jugular venous pressure or a third heart sound was ascertained by physical examination on entry into the trial. The risks of hospitalization for heart failure and progression of heart failure as defined by death from pump failure and the composite end point of death or hospitalization for heart failure were compared in patients with these findings on physical examination and patients without these findings. RESULTS: Data on 2479 patients were complete and analyzed. In multivariate analyses that were adjusted for other markers of the severity of heart failure, elevated jugular venous pressure was associated with an increased risk of hospitalization for heart failure (relative risk, 1.32; 95 percent confidence interval, 1.08 to 1.62; P<0.01), death or hospitalization for heart failure (relative risk, 1.30; 95 percent confidence interval, 1.11 to 1.53; P<0.005), and death from pump failure (relative risk, 1.37; 95 percent confidence interval, 1.07 to 1.75; P<0.05). The presence of a third heart sound was associated with similarly increased risks of these outcomes. CONCLUSIONS: In patients with heart failure, elevated jugular venous pressure and a third heart sound are each independently associated with adverse outcomes, including progression of heart failure. Clinical assessment for these findings is currently feasible and clinically meaningful.
Authors: Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder S Anand; Jean L Rouleau; Akshay S Desai; Eldrin F Lewis; Muthiah Vaduganathan; Stephen Y Wang; Bertram Pitt; Nancy K Sweitzer; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2019-06-21 Impact factor: 8.790
Authors: Michel Zuber; Christine H Attenhofer Jost; Peter Kipfer; Sean P Collins; Frank Michota; W Frank Peacock Journal: Ann Noninvasive Electrocardiol Date: 2007-10 Impact factor: 1.468
Authors: Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling Journal: Nat Rev Nephrol Date: 2016-08-30 Impact factor: 28.314
Authors: Larry A Allen; Marco Metra; Olga Milo-Cotter; Gerasimos Filippatos; Leonardo H Reisin; Daniel R Bensimhon; Edoardo G Gronda; Paolo Colombo; G Michael Felker; Livio Dei Cas; Dimitrios T Kremastinos; Christopher M O'Connor; Gadi Cotter; Beth A Davison; Howard C Dittrich; Eric J Velazquez Journal: J Card Fail Date: 2008-08-15 Impact factor: 5.712